These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 39020428

  • 1. Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.
    Cooper TT, Dieters-Castator DZ, Liu J, Siegers GM, Pink D, Veliz L, Lewis JD, Lagugné-Labarthet F, Fu Y, Steed H, Lajoie GA, Postovit LM.
    J Ovarian Res; 2024 Jul 17; 17(1):149. PubMed ID: 39020428
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
    Vyhlídalová Kotrbová A, Gömöryová K, Mikulová A, Plešingerová H, Sladeček S, Kravec M, Hrachovinová Š, Potěšil D, Dunsmore G, Blériot C, Bied M, Kotouček J, Bednaříková M, Hausnerová J, Minář L, Crha I, Felsinger M, Zdráhal Z, Ginhoux F, Weinberger V, Bryja V, Pospíchalová V.
    J Extracell Vesicles; 2024 Mar 17; 13(3):e12420. PubMed ID: 38490958
    [Abstract] [Full Text] [Related]

  • 4. Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma.
    Herzog M, Verdenik I, Kobal B, Černe K.
    Int J Mol Sci; 2024 Jun 20; 25(12):. PubMed ID: 38928484
    [Abstract] [Full Text] [Related]

  • 5. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF, He LS, Zhang ZD, Huang QS.
    Asian Pac J Trop Med; 2012 Dec 20; 5(12):925-30. PubMed ID: 23199707
    [Abstract] [Full Text] [Related]

  • 6. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.
    Gynecol Oncol; 2018 Jun 20; 149(3):585-591. PubMed ID: 29572027
    [Abstract] [Full Text] [Related]

  • 7. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.
    Kandimalla R, Wang W, Yu F, Zhou N, Gao F, Spillman M, Moukova L, Slaby O, Salhia B, Zhou S, Wang X, Goel A.
    Clin Cancer Res; 2021 Aug 01; 27(15):4277-4286. PubMed ID: 34035068
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
    Tessier-Cloutier B, Cochrane DR, Karnezis AN, Colborne S, Magrill J, Talhouk A, Zhang J, Leung S, Hughes CS, Piskorz A, Cheng AS, Greening K, du Bois A, Pfisterer J, Soslow RA, Kommoss S, Brenton JD, Morin GB, Gilks CB, Huntsman DG, Kommoss F.
    Hum Pathol; 2020 Jul 01; 101():40-52. PubMed ID: 32360491
    [Abstract] [Full Text] [Related]

  • 10. Tandem SERS and MS/MS Profiling of Plasma Extracellular Vesicles for Early Ovarian Cancer Biomarker Discovery.
    Veliz L, Cooper TT, Grenier-Pleau I, Abraham SA, Gomes J, Pasternak SH, Dauber B, Postovit LM, Lajoie GA, Lagugné-Labarthet F.
    ACS Sens; 2024 Jan 26; 9(1):272-282. PubMed ID: 38214491
    [Abstract] [Full Text] [Related]

  • 11. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.
    Bradbury M, Borràs E, Vilar M, Castellví J, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Santamaria A, Sabidó E.
    J Transl Med; 2022 Dec 21; 20(1):611. PubMed ID: 36544142
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C, Wang Y, Wang X, Zhang Q, Li Y, Xu Y, Jin C, Bu H, Zheng W, Yang X, Lu N, Kong B.
    Int J Oncol; 2018 Jun 21; 52(6):2041-2050. PubMed ID: 29620196
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma.
    Wenk D, Khan S, Ignatchenko V, May T, Bernardini MQ, Kislinger T.
    J Proteome Res; 2024 Feb 02; 23(2):749-759. PubMed ID: 38266179
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers.
    Yamamoto CM, Oakes ML, Murakami T, Muto MG, Berkowitz RS, Ng SW.
    J Ovarian Res; 2018 Mar 02; 11(1):20. PubMed ID: 29499737
    [Abstract] [Full Text] [Related]

  • 20. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
    Kim SI, Hwangbo S, Dan K, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Han D, Lee M.
    Mol Cell Proteomics; 2023 Mar 02; 22(3):100502. PubMed ID: 36669591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.